# GARDASIL Reexamination Study (V501-059)

> **NCT01062074** · — · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 3605 (actual)

## Conditions studied

- Human Papillomavirus (HPV) Infection

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01062074
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09-28
- **Primary completion:** 2013-05-07
- **Final completion:** 2013-05-07
- **Target enrollment:** 3605 (ACTUAL)
- **Last updated:** 2017-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01062074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01062074, "GARDASIL Reexamination Study (V501-059)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01062074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*